Daiichi pulls out of India with closure of 170-strong R&D plant
pharmafile | January 11, 2017 | News story | Manufacturing and Production, Research and Development | Daiichi Sankyo, Ranbaxy, Sun Pharma
Japanese pharma firm Daiichi Sankyo has announced its intention to close its R&D centre in Gurgaon, India, a step in its global restructuring programme in the hopes of “decreasing R&D operations costs and redistributing resources to the further development of its R&D pipeline.”
The decision comes only a year after the company announced the closure of an antibody production plant in Germany and a UK facility as part of this global plan.
The facility employs 170 staff engaged in drug discovery research, though it is currently unclear how they will be affected by the move. All R&D function will be transferred to the company’s Japanese division, effectively ending Daiichi’s presence in India.
The company originally acquired the facility as part of its takeover of India’s largest generic drugs manufacturer Ranbaxy in 2008, but after some troubling years and import bans and misconduct charges from the FDA, Daiichi was forced to sell the ailing firm to Sun Pharmaceuticals for $4 billion in 2014.
Matt Fellows
Related Content
FDA accepts BLA for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for breast cancer treatment
AstraZeneca and Daiichi Sankyo have announced that their Biologics License Application (BLA) for datopotamab deruxtecan …
EMA validates two applications for datopotamab deruxtecan for cancer treatments
AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …
Daiichi Sankyo shares results for Ezharmia as lymphoma treatment
Daiichi Sankyo has announced results from the phase 2 VALENTINE-PTCL01 trial of Ezharmia (valemetostat tosilate), …